Frazier Life Sciences Management, L.P. Cerevel Therapeutics Holdings, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.7 Billion
- Q2 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 393,000 shares of CERE stock, worth $0. This represents 0.95% of its overall portfolio holdings.
Number of Shares
393,000
Previous 393,000
-0.0%
Holding current value
$0
Previous $16.6 Million
3.27%
% of portfolio
0.95%
Previous 0.87%
Shares
3 transactions
Others Institutions Holding CERE
# of Institutions
21Shares Held
5.93MCall Options Held
27.3KPut Options Held
0-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Segantii Capital Management LTD1.14MShares$05.99% of portfolio
-
Jane Street Group, LLC New York, NY270KShares$00.01% of portfolio
-
Tekla Capital Management LLC176KShares$00.22% of portfolio
-
Credit Suisse Ag Zurich, V8112KShares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...